Yourgene Health launches first oncology product

Writer,

Molecular diagnostics group Yourgene Health said it had launched its first oncology product.

The Elucigene DPYD assay was a chemotoxicity diagnostic assay that could identify cancer patients with Dihydropyrimidine Dehydrogenase deficiency.

The condition can cause severe and sometimes lethal side effects in patients being treated with chemotherapeutic drug 5-Fluorouracil, commonly used in the treatment of colon, oesophageal, stomach, pancreatic, breast and cervical cancers.


Related content

Yourgene Health launches genomic services offering

Molecular diagnostics group Yourgene Health said it had launched a genomic services offering.

The company said the offering was an integration and expansion of its...

Mon, 28/09/2020 - 09:28


Yourgene Health inks US distribution pact with Immuno-Biological Laboratories

Molecular diagnostics group Yourgene Health said it had appointed Immuno-Biological Laboratories as a non-exclusive distributor for several of its tests across its reproductive health and...

Mon, 21/09/2020 - 07:15


Yourgene Health launches IONA Nx NIPT workflow

Molecular diagnostics group Yourgene Health has announced the launch of IONA Nx NIPT workflow, a new non-invasive prenatal test (NIPT).

The group said the IONA...

Thu, 03/09/2020 - 09:23


Yourgene Health raises £16.2m to fund acquisition of Coastal Genomics

Molecular diagnostics group Yourgene Health said it expected to raise £16.2m via a share issue to help fund its acquisition of Vancouver-based sample preparation company...

Wed, 05/08/2020 - 07:48


Yourgene Health gets CE mark for SARS-CoV-2 test

Molecular diagnostics group Yourgene Health said it had achieved CE-IVD marking for its SARS-CoV-2 test.

The company said the CE-IVD version of its Clarigene test...

Mon, 03/08/2020 - 07:55